Methadone-associated Q-T interval prolongation and torsades de pointes (Q33157337)

23 July 2017

1 reference

title

Methadone-associated Q-T interval prolongation and torsades de pointes (English)

1 reference

23 July 2017

1 reference

John Stringer

1

1 reference

PubMed ID

19386945

23 July 2017

Christopher Welsh

series ordinal

2

1 reference

PubMed ID

19386945

23 July 2017

Anthony Tommasello

series ordinal

3

1 reference

23 July 2017

1 May 2009

1 reference

American Journal of Health-System Pharmacy

23 July 2017

1 reference

23 July 2017

66

1 reference

23 July 2017

825-833

1 reference

23 July 2017

9

1 reference

Molecular physiology of cardiac repolarization

23 July 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Electrocardiographic quantitation of ventricular repolarization.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Drug-induced torsades de pointes and implications for drug development.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

hERG potassium channels and cardiac arrhythmia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Long QT syndrome: reduced repolarization reserve and the genetic link

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QTc dispersion in haemodialysis patients with cardiac complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Impairment of human ether-à-go-go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

The congenital long QT syndromes from genotype to phenotype: clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Low penetrance in the long-QT syndrome: clinical impact

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Genetic basis of drug-induced arrhythmias

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

The effect of heroin and multiple drug abuse on the electrocardiogram

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Chronic methadone therapy complicated by torsades de pointes: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Qt prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Torsade de pointes due to methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Torsades de pointes during methadone treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QT prolongation and syncope with methadone, doxepin, and a beta-blocker

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

High dose methadone and ventricular arrhythmias: a report of three cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QTc prolongation and torsades de pointes associated with methadone therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Maternal methadone may cause arrhythmias in neonates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Torsade de pointes associated with very-high-dose methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QTc interval prolongation associated with intravenous methadone.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

The impact of methadone induction on cardiac conduction in opiate users

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QTc interval prolongation in patients on long-term methadone maintenance therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

A community-based evaluation of sudden death associated with therapeutic levels of methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Induction with levomethadyl acetate: safety and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Exposure to opioid maintenance treatment reduces long-term mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Role of implantable cardioverter-defibrillators in patients with methadone-induced long QT syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Treatment of torsade de pointes with magnesium sulfate.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

Clinical and therapeutic aspects of congenital and acquired long QT syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070392

31 March 2020

Identifiers

DOI

10.2146/AJHP070392

1 reference

23 July 2017

1 reference

PubMed ID

19386945